Abstract. Four transmembrane tyrosine kinases constitute the ErbB protein family: epidermal growth factor receptor (EGFR) or ErbB1, ErbB2, ErbB3, and ErbB4. In general, the structure and mechanism of the activation of these members are similar. However, significant differences in homologous desensitization are known between EGFR and ErbB4. Desensitization of ligand occupied EGFR occurs by endocytosis, while that of ErbB4 occurs by selective cleavage at the cell surface. Because ErbB4 is abundantly expressed in neurons from fetal to adult brains, elucidation of the desensitization mechanism is important to understand neuronal development and synaptic functions. Recently, it has become clear that heterologous desensitization of EGFR and ErbB4 are induced by endocytosis and cleavage, respectively, similar to homologous desensitization. It has been reported that heterologous desensitization of EGFR is induced by serine phosphorylation of EGFR via the p38 mitogenactivated protein kinase (p38 MAP kinase) pathway in various cell lines, including alveolar epithelial cells. In contrast, the protein kinase C pathway is involved in ErbB4 cleavage. In this review, we will describe recent advances in the desensitization mechanisms of EGFR and ErbB4, mainly in alveolar epithelial cells and hypothalamic neurons, respectively.
Introduction
Epidermal growth factor receptor (EGFR) belongs to the ErbB protein family of receptor tyrosine kinases (1, 2) . When EGF binds to the receptor, tyrosine kinase is activated and multiple tyrosine residues are auto phosphorylated, resulting in the initiation of multiple signal transduction pathways (1, 2) . At the same time, homologous desensitization occurs: the EGFoccupied EGFR is rapidly internalized by receptormediated endo cytosis (2) (Fig. 1A) . The internalized EGFR is sorted to lysosomes where it is degraded (Table 1 ). This desensi tization plays crucial roles in regulating cellular events triggered by EGFR stimulation. However, other members of the ErbB family, ErbB2, ErbB3, and ErbB4, are not efficiently internalized (3) . In several cell lines, ErbB4 is instead cleaved after stimulation by its ligand, neuregulin (NRG), also known as heregulin, producing a cyto plasmic domain fragment of 80 kDa and a soluble ectodomain of 120 kDa (3) (Fig. 1B) . This means that homologous desensitization of ErbB4 is induced by selective proteolysis at the cell surface without internal ization (Table 1) . Desensitization followed by ligand binding is called homologous desensitization ( Fig. 1) , while desensitization induced by some treatments with out ligand binding is called heterologous desensitization (2, 4) (Figs. 2B and 3B ). In the case of ErbB4, robust cleavage has been reported for plateletderived growth factor and the protein kinase C activator, phorbol 12 myristate 13acetate (PMA) (4) . It was reported that a protein kinase C inhibitor blocked PMAinduced cleavage of ErbB4, but did not inhibit NRGinduced cleavage in breast carcinoma cells (3) . These results Accumulating evidence indicates that heterologous desensitization of EGFR is induced by endocytosis after serine phosphorylation of EGFR via the p38 mitogenactivated protein kinase (p38 MAP kinase) pathway in various cell lines, including alveolar epithelial cells. In contrast, it has been reported that heterologous desensi tization of ErbB4 is induced by the activation of the protein kinase C pathway. In this review, we will describe the regulation of EGFR and ErbB4 mainly in alveolar epithelial cells and hypothalamic neurons, respectively, using our recent data.
Desensitization by Different Strategies of Epidermal Growth Factor Receptor and ErbB4

Regulation of EGFR in alveolar epithelial cells
Transactivation and desensitization of EGFR by tumor necrosis factor a (TNFa)
Some treatments induce shedding of precursors of the ligands for ErbB family to release the ligands to the extracellular milieu. The released ligands bind to their cognate ErbB family receptors of the same cell and acti vate the receptors ( Figs. 2A and 3A ). This activation is called transactivation of the receptor (5) . Ligand binding to the receptor is necessary for transactivation, while heterologous desensitization occurs without ligand binding (Figs. 2 and 3 ). TNFa, a cytokine involved in various cellular functions (5, 6) , reportedly transactivated EGFR through soluble transforming growth factor a (TGFa) in the AML12 hepatocyte cell line (5) (Fig. 2A) . The transactivation mechanisms involved cell surface matrix metalloproteases that released TGFa from pro TGFa anchored in the plasma membrane (5) . In addition to these effects, TNFa reportedly activated the p38 MAP kinase pathway and induced the phosphorylation of EGFR at serine 1047 (Ser1047) (7) (Fig. 2B) . The phosphorylated EGFR was internalized through a clathrin mediated mechanism (7), suggesting that TNFa induced heterologous desensitization as well as transactivation of EGFR. The heterologous desensitization of EGFR may be involved in p38 MAP kinase-mediated apoptosis in lung cells, as reported (8) . It was interesting that EGFR phosphorylated at Ser1047 was not degraded at lyso somes and that inactivation of the p38 MAP kinase pathway led to dephosphorylation of EGFR and its recycling back to the cell surface (Fig. 2B) . In spite of all these data, a protein kinase that is activated by p38 MAP kinase and directly phosphorylates EGFR at Ser1047 remains to be elucidated.
Transactivation and phosphorylation of EGFR by TNFa in A549 cells
A549 cells are immortalized alveolar epithelial cells, and this cell line has been used as a model to study the responses of alveolar epithelial cells to several treatments (9, 10). When we treated A549 cells with TNFa, the phosphorylation of EGFR at Tyr1173 increased approxi mately 12fold at 15 min, declining at 30 min (11) , suggesting that TNFa treatment transactivated EGFR, Fig. 2 . Schematic representation of transactivation (A) and desensi tization (B) of EGFR by TNFa. Both TNFa and its receptors are trimers. In the case of transactivation, tyrosine residues, including Tyr1173, are autophosphorylated following the binding of TGFa to EGFR (A). EGFoccupied EGFR was reportedly autophosphorylated at Tyr1045, while it is not clear whether or not TGFaoccupied EGFR is also autophosphorylated at Tyr1045 in addition to Tyr1173 (see the text). There are some reports that TACE is involved in the shedding of proTGFa. In the case of desensitization (B), Ser1047 is phos phorylated following activation of the p38 MAP kinase pathway. as reported in cultured hepatocytes (5) . In addition, phosphorylation of EGFR at Ser1047 was detected at 5 min, peaked at 15 min, and declined at 30 min. The phosphorylation of Ser1047 by TNFa was increased approximately 100fold at 15 min. We found that p38 MAP kinase was activated by TNFa with a time course similar to that for the phosphorylation of Ser1047. SB203580, a specific inhibitor of p38 MAP kinase, completely inhibited the phosphorylation of Ser1047. EGFinduced ubiquitination of EGFR has been well studied in other cell types (12) , while no ubiquitination of EGFR was observed in A549 cells (11).
MAP
kinase-activated protein kinase-2 (MAPKAPK-2), a protein kinase responsible for phosphorylation of Ser1047
MAPKAPK2 is a protein kinase downstream of p38 MAP kinase that is activated by multisite phosphoryla tion by p38 MAP kinase (13) . One physiological sub strate for MAPKAPK2 is heat shock protein 27 (HSP27) (13) . HSP27 is phosphorylated at Ser78 and Ser82, both of which occur in the sequence motif RXXS (14) . The primary amino acid sequence around Ser1047 in EGFR is RYSSDP, and Ser1047 is also in the RXXS motif. Therefore, we examined whether MAPKAPK2 was responsible for the phosphorylation of Ser1047 (11) . It was reported that phosphorylation of any two of the residues, Thr222, Ser272, and Thr334, was necessary and sufficient for maximal activation of MAPKAPK2 (15) . MAPKAPK2 was phosphorylated at Thr222 and Thr334 after TNFa treatment, indicating MAPKAPK2 activation (11) . In addition to SB203580, a MK2a inhibi tor that binds to MAPKAPK2 and prevents its activa tion, inhibited the TNFainduced phosphorylation of Ser1047 (11) . These results suggested that MAPKAPK2 was involved in the TNFainduced phosphorylation of Ser1047.
Phosphorylation of EGFR at Ser1047 in vitro by MAPKAPK-2
It was reported that bacterially overexpressed MAPKAPK2 fused with GST (GSTMAPKAPK2) was inactive and could be activated by extracellular signalregulated kinase (ERK) as well as p38 MAP kinase (15) . Following this report, we bacterially over expressed and purified GSTMAPKAPK2, and mea sured the activity of GSTMAPKAPK2 with syntide2 and [g 32 P]ATP. We confirmed that GSTMAPKAPK2 was activated more than 120fold by incubation with preactivated ERK and ATP (11) . We then overexpressed EGFR in HEK293T cells and immunoprecipitated it, followed by phosphorylation with activated GST MAPKAPK2. Immunoblot analysis showed that GST MAPKAPK2 could phosphorylate Ser1047 in vitro. Taken together, it is highly possible that MAPKAPK2 is responsible for TNFainduced phosphorylation of EGFR at Ser1047.
Regulation by flagellin of EGFR in alveolar epithelial cells
Flagellin, a primary structural component of bacterial flagella, binds to and activates Tolllike receptor 5 (TLR5) in vertebrates (16) . It is well known that stimulation of TLR5 by flagellin activates the gene expression of proinflammatory cytokines such as interleukin8 in intestinal epithelial cells (17) . Legionella pneumophila is flagellated bacteria. We have been investigating the pathophysiological roles of TLR5 in pulmonary infection of Legionella pneumophila. TLR5 reportedly recognized 13 amino acid residues in flagellin, and all these amino acids are conserved both in Bacillus subtilis and in Legionella pneumophila (18, 19) . Therefore, we treated A549 cells with flagellin purified from Bacillus subtilis to stimulate TLR5 and we found that TLR5 stimulation induced epithelialmesenchymal transition in A549 cells (20) . In addition, p38 MAP kinase was activated by flagellin most strongly among the MAP kinases tested: ERK, p38 MAP kinase, and cjun Nterminal kinase (20).
Phosphorylation of EGFR by flagellin in A549 cells
We found that phosphorylation of EGFR at Ser1047 was increased by flagellin treatment approximately 18 fold at 30 min, compared with the control (11) . Although phosphorylation by flagellin was weaker than that by TNFa, phosphorylation was sustained, and an approxi mately 17fold increase was still observed at 120 min. In contrast, no increase in phosphorylation at Tyr1173 was observed, suggesting that flagellin did not transactivate EGFR. MK2a inhibitor as well as SB203580 abolished the phosphorylation of Ser1047. These results strongly suggested that MAPKAPK2 activated by p38 MAP kinase was responsible for the phosphorylation of Ser1047 following flagellin treatment. Flagellin may induce the internalization of EGFR, as reported in TNFa (7).
Regulation of EGFR and ErbB4 in hypothalamic neurons
Transactivation by Gonadotropin-releasing hormone (GnRH) of EGFR and ErbB4 in GT1-7 cells
GnRH is secreted from hypothalamic neurons (GnRH neurons). GnRH neurons have a GnRH receptor belong ing to the Gprotein-coupled receptors (GPCRs). GT17 cells retain many of the characteristics of native GnRH neurons, including the expression of GnRH receptors (21, 22) . This cell line has been used to study the intra cellular signal transduction mechanisms induced by GnRH receptor stimulation (21, 23) . It has been reported that GnRH activates ERK via transactivation of EGFR in the cells (24) (Fig. 3A) . Transactivation of EGFR occurs through ectodomain shedding of proheparin binding-EGF (proHBEGF) and the release of soluble HBEGF. It is well known that HBEGF binds to both EGFR and ErbB4 and provokes the activation of the receptors (1). We found that GT17 cells expressed ErbB4 as well as EGFR and that the knockdown of ErbB4 significantly inhibited the GnRHinduced activation of ERK (25) . These results clearly indicated that ErbB4 as well as EGFR was involved in GnRHinduced ERK activation, in other words, GnRH transactivated both EGFR and ErbB4 (Fig. 3A) .
Cleavage of ErbB4 after GnRH treatment
In order to confirm that tyrosine residues in ErbB4 were autophosphorylated following GnRH treatment, we performed immunoblot analysis of ErbB4. It was surprising that the protein level of ErbB4 was markedly decreased by GnRH treatment, and an 80kDa fragment appeared (25) (Fig. 3B) . After treatment of the cells with 50 nM GnRH for 5 min, about 80% of ErbB4 was cleaved. We confirmed that GnRH increased phosphory lation of EGFR at Tyr1173, while no cleavage of EGFR was observed (25) . The cleavage of ErbB4 was com pletely inhibited by antide, a GnRH antagonist, indicat ing that the effect of GnRH was receptormediated. As described above, it was reported that PMA treatment of NIH 3T3 cells induced cleavage of the overexpressed ErbB4 and produced an 80kDa fragment (4). We con firmed that PMA treatment of GT17 cells induced the cleavage of ErbB4, but the effect of PMA treatment was weaker than that of GnRH treatment (25) . As reported in NIH3T3 cells, PMA treatment produced an 80kDa fragment, which comigrated with the GnRH produced fragment.
Comparison of ERK activation and ErbB4 cleavage after GnRH treatment
We compared ERK activation and ErbB4 cleavage with increasingly higher concentrations of GnRH for 5 or 30min treatment (25) . ERK activation was observed at 0.1 nM and peaked at 1 nM for either time interval. In contrast, ErbB4 cleavage was observed at 1 nM and peaked at 25 nM. When we compared the time course with 1 and 25 nM GnRH, ERK activation and ErbB4 cleavage peaked at 5 and 30 min, respectively, with either concentration. These results indicated that a higher concentration and longer treatment were neces sary for GnRH to induce ErbB4 cleavage than ERK activation. It is not clear at present whether ErbB4 transactivation is prerequisite for ErbB4 cleavage.
It was reported that TNFaconverting enzyme (TACE) (also known as ADAM 17) was required for the cleavage of ErbB4 by PMA in fibroblasts (26) . We confirmed that a TACE inhibitor (TAPI2) and siRNAs for TACE inhibited ErbB4 cleavage (25) . Therefore, it is highly possible that ErbB4 is cleaved by TACE at the same site on both PMA and GnRH treatments of GT17 cells (Fig. 3B) . In contrast, TAPI2 did not inhibit ERK acti vation, indicating that TACE was not involved in the shedding of proHBEGF: transactivation of EGFR and ErbB4 in GT17 cells.
Desensitization of ErbB4 by GnRH treatment
Phosphorylation of ERK by GnRH was transient, and when we treated the cells with GnRH for 5 min and withdrew GnRH by changing the medium, dephosphory lation of ERK was almost complete at 45 min. In contrast, about 6 h were required for the native ErbB4 to recover to the basal level. Biotinylation of the cell surface pro teins indicated that the cell surface ErbB4 was selectively cleaved by GnRH (25) . In order to further confirm the desensitization of ErbB4, we treated GT17 cells with NRG1 that stimulates ErbB4 but not EGFR. ERK was significantly activated by treatment with NRG1, and the activation was increased about 3fold at 5 min. In contrast, after 5min incubation with GnRH and 90min incubation with GnRHfree medium, NRG1 did not activate ERK at all. These results clearly indicated the desensitization of ErbB4 after GnRHinduced cleavage of ErbB4. To our knowledge, this appears to be the first report about the heterologous desensitization of ErbB4 by any GPCR stimulation.
Concluding remarks
Because EGFR and ErbB4 have crucial roles in the cell functions of various tissues, it is important to eluci date the molecular mechanisms of their desensitization. Table 1 summarizes the homologous and heterologous desensitization of EGFR and ErbB4. Phosphorylation of EGFR at Tyr1045 reportedly induced the internalization of EGFoccupied EGFR, followed by degradation (12) . In contrast, it has been reported that desensitization induced by phosphorylation at Ser1047 is reversible and can escape degradation (7) . Because Ser1047 is close to Tyr1045, it is worth examining whether prephosphory lation at Ser1047 inhibits or activates phosphorylation at Tyr1045.
In addition to the desensitization of ErbB4, ErbB4 cleavage may have some additional physiological roles (27, 28) . It has been reported that the 80kDa fragment translocates to the nucleus and that transcription factors are chaperoned into the nucleus with the 80kDa frag ment (27) (Fig. 3B) . Therefore, the 80kDa fragment may affect gene expression (27, 28) . It is also possible that the released extracellular domain of ErbB4 binds HBEGF and NRG in the extracellular milieu to block their signal transductions. Although these possibilities have been proposed for almost 20 years, they have still not been elucidated and should be pursued.
